brexucabtagene autoleucel
gilead sciences
['tecartus', 'cart,(-cartitude)', 'leusm', 'zuma-3']
#asco22 #leusm leonard: long-term tecartus data show those w &gt;75% blasts at baseline (pre-apheresis) hv risk for poor outcome (29% 2yr os vs 58-80% in lower blast groups). 6/55 pts on zuma-3 remain in cr wo subsequent allo (may hv had prior allo, tho, which affects decision). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)